troglitazone has been researched along with Hemangioma in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Hemangioma: A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000)
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duddy, SK | 1 |
| Parker, RF | 1 |
| Bleavins, MR | 1 |
| Gough, AW | 1 |
| Rowse, PE | 1 |
| Gorospe, S | 1 |
| Dethloff, LA | 1 |
| de la Iglesia, FA | 1 |
1 other study available for troglitazone and Hemangioma
| Article | Year |
|---|---|
p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone.
Topics: Animals; Antioxidants; Chromans; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene | 1999 |